Abstract
Major Depressive Disorder (MDD) treatment often involves a trial-and-error approach with Selective Serotonin Reuptake Inhibitors (SSRIs). While personality traits are known to correlate with MDD and treatment outcomes, the genetic basis of this link remains under-explored. This study examines whether polygenic scores (PGSs) for the Big Five personality traits can predict SSRI response and remission. Analyzing data from the PGRN-AMPS and ISPC cohorts, we found significant associations for openness, neuroticism, and conscientiousness. Furthermore, cross-trait GWAS meta-analyses identified eight shared genetic loci, highlighting potential molecular pathways connecting personality and antidepressant efficacy.
Introduction
Treating Major Depressive Disorder is a significant clinical challenge, with only about half of patients responding to first-line SSRIs and even fewer achieving full remission. Psychological research has long linked personality traits—specifically high neuroticism and low conscientiousness—to poorer treatment outcomes. However, it has been unclear if these associations are purely behavioral or reflect a shared genetic architecture. This study leverages polygenic scores to investigate the "polygenic load" of personality traits as a predictor for medication response, moving toward a more personalized approach in psychiatry.
Methods
The researchers analyzed genomic data from 1,394 MDD patients across two cohorts: the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS, $n=529$) and the International SSRI Pharmacogenomics Consortium (ISPC, $n=865$).
Two primary analytical methods were used:
- Polygenic Scores (PGS): Weighted sums of thousands of genetic variants (SNPs) derived from large-scale external GWAS of personality traits.
- Cross-Trait GWAS Meta-Analysis: Identification of specific genetic loci influencing both personality traits and SSRI outcomes using O’Brien’s (OB) and direct Linear Combination (dLC) methods.
Results
The analysis revealed that genetic predispositions for certain personality traits significantly correlate with how patients respond to SSRIs.
Key Findings by Trait
- Openness: PGS for openness was a significant predictor of both response and remission. It accounted for approximately 1.5% of the variation in response and 2.8% in remission. The data suggested that openness genetics might influence the tempo of recovery, with different effects observed at 4-week versus 8-week intervals.
- Neuroticism: High genetic neuroticism was a consistent predictor of lower remission odds. Patients in the highest quartile of neuroticism PGS had roughly 50% lower odds of achieving remission compared to those in the lowest quartile.
- Conscientiousness: In the PGRN-AMPS cohort, patients with a high polygenic load for conscientiousness had nearly double the odds (1.95x) of a favorable response at 4 weeks.
Shared Molecular Machinery
The cross-trait meta-analysis identified eight specific loci that overlap between personality and drug response:
- Conscientiousness and Response: One locus near the YEATS4 gene.
- Neuroticism and Remission: Seven loci near genes including PRAG1, MSRA, XKR6, ELAVL2, PLXNC1, PLEKHM1, and BRUNOL4.
Discussion
These results provide evidence that the link between personality and antidepressant response is rooted in shared molecular pathways. The identification of the YEATS4 locus is particularly noteworthy, as this gene's expression has previously been linked to antidepressant dosage in animal models.
While the variance explained by these genetic scores (1.5–3%) is currently small for standalone clinical diagnostics, they represent a significant step toward precision psychiatry. Future work should focus on larger sample sizes to increase predictive power and the integration of PGS into multi-variable clinical models that include environmental and psychological data.
Conclusion
Polygenic scores for personality traits offer a promising tool for predicting SSRI treatment outcomes in MDD patients. By uncovering the shared genetic architecture between personality and pharmacology, this research paves the way for more tailored and effective treatment strategies in mental health care.
Summary updated